5 Things Amgen Investors Want to Know When It Reports Its Q3 Results
Instead of focusing on Amgen's headline numbers, pay attention to whether its quarterly report answers these five considerably more important questions.
4 Blockbuster Drugs Whose Sales Could Easily Double
These drugs are already generating -- or on pace to generate -- more than $1 billion in annual sales, yet they're capable of so much more.
Celgene Presents Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis
Celgene Presents Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis at UEG Week
3 Top Stocks to Buy for Your Kids/Grandkids
Our contributors think that these 3 healthcare stocks can give your kids a financial head start in life.
Specialty Drug Classes That Are Costing Consumers an Arm and a Leg
Specialty drug costs as a whole rose by 25% in 2014 according to the nation's largest pharmacy-benefit manager. The following specialty therapy classes appear to be the primary culprits behind these price hikes.